Anxiety disorders are some of the most common conditions we encounter in children and adolescents, and clinicians employ a variety of medications to treat them. This study examined prescribing patterns for the initial treatment of pediatric anxiety.

Treating sleep problems in youth with autism spectrum disorder (ASD) is tricky at best. One promising treatment is pediatric prolonged-release melatonin ­(PedPRM) sold under the name Slenyto.

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits.

After reading these articles, you should be able to…

This double issue was long in the making. We contacted a number of experts in the world of trauma, from Jeff Max on traumatic brain injury to Suzan Song on helping refugees. We also spoke with Stuart Shanker about what we could learn from his experience in developing mass education on self-regulation in children. And as promised, we have responded to the recent reports of increased mortality in children taking “higher” doses of antipsychotic medications.

There are reports of increased mortality from antipsychotics in older adults. Now, we have a paper showing increased mortality in children, adolescents, and young adults aged 5–24 years. Given the frequent use, both on- and off-label, of antipsychotics, does this change how we use them? And if so, how?

Mild traumatic brain injury (mTBI) accounts for about 90% of all TBI cases in children and adolescents, or about 180 out of every 100,000 cases in the US. With 2 million cases between 2005 and 2009, we are seeing many patients who have TBI as part of their history. How does it affect them?